 A randomized, double-blind, placebo-controlled, parallel grouped, clinical study will be conducted to evaluate the antihypertensive efficacy and tolerability and to determine adequate antihypertensive dosage of FimasartanBR-A-657-K in patients with mild to moderate essential hypertension. 